{"created":"2023-05-15T16:49:12.122586+00:00","id":26540,"links":{},"metadata":{"_buckets":{"deposit":"cf96aedf-6f7a-4e1c-aef4-7ba32090334d"},"_deposit":{"created_by":6,"id":"26540","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"26540"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00026540","sets":["10:22:24"]},"author_link":["117887","117886"],"item_5_alternative_title_19":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"年齢、症候性転移病変、癌性胸水は、レンバチニブで治療された分化型甲状腺癌患者の予後不良因子である。"}]},"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-03-22","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"77","bibliographicPageStart":"71","bibliographicVolumeNumber":"63","bibliographic_titles":[{"bibliographic_title":"Acta Medica Nagasakiensia"}]}]},"item_5_date_granted_64":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2021-03-22"}]},"item_5_degree_grantor_62":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_name":"Nagasaki University (長崎大学)"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"17301","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_5_degree_name_61":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士(医学)"}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Lenvatinib is one of the few therapeutic options available for radioiodine-refractory thyroid cancer. However, the factors that determine the therapeutic outcomes remain unknown.\nMethods: Patients with thyroid carcinoma treated with lenvatinib who had been dead or who had survived for longer than a halfyear were retrospectively compared. We evaluated the clinical parameters when lenvatinib was started, and also studied the tumor volume reduction ratio, the duration until re-growth of the largest metastatic lesion, the thyroglobulin (Tg) reduction rate, and the duration until re-elevation of Tg after lenvatinib between survivors and dead patients.\nResults: We identified 16 patients, with an average age of 73.1±7.6 yrs and a male-to-female ratio of 5 to 11, who had advanced differentiated thyroid cancer that was treated with lenvatinib. Nine patients had died after 8.9±6.1 months, whereas 7 survived for 13.0±2.0 months after starting lenvatinib. The patients who died were older than the survivors (76.7±6.5 vs. 68.6±6.6 yrs, p=0.03). Malignant pleural effusion (p=0.017) and symptomatic metastatic disease (SMD) (p=0.039) were associated with death in a Kaplan-Meier survival analysis. Age (p=0.012, HR 1.150, CI 1.030-1.320) and SMD (p=0.014, HR 8.069, CI 1.503-61.34) were associated with poor outcome in a multivariate Cox proportional hazard model. The duration until the re-elevation of Tg was longer in survivors than in patients who died (6.43±4.55 vs. 2.17±1.39 months, p=0.025).\nConclusions: We identified multiple factors, including SMD, that were related to poor outcomes after lenvatinib treatment. This study suggests that lenvatinib might be started before patients develop SMD.","subitem_description_type":"Abstract"}]},"item_5_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"長崎大学学位論文 学位記番号:共博(医歯薬)甲第9号 学位授与年月日:令和3年3月22日","subitem_description_type":"Other"},{"subitem_description":"Author: Yomi Nakashima, Takao Ando, Aya Nozaki, Ayako Ito, Ichiro Horie, \nMisa Imaizumi, Toshiro Usa and Atsushi Kawakami","subitem_description_type":"Other"},{"subitem_description":" Acta Medica Nagasakiensia, 63, pp.71−77; 2020","subitem_description_type":"Other"}]},"item_5_description_69":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Nagasaki University (長崎大学), 博士(医学) (2021-03-22)","subitem_description_type":"Other"}]},"item_5_dissertation_number_65":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲共医歯薬第9号"}]},"item_5_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"117887","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Nakashima, Yomi"}]}]},"item_5_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nagasaki University School of Medicine"}]},"item_5_relation_42":{"attribute_name":"関係URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://hdl.handle.net/10069/40722","subitem_relation_type_select":"HDL"}}]},"item_5_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"(C) 2020 Nagasaki University School of Medicine"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00016055","subitem_source_identifier_type":"ISSN"}]},"item_5_text_67":{"attribute_name":"学位の種類","attribute_value_mlt":[{"subitem_text_value":"課程博士"}]},"item_5_text_68":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"長崎大学医学部"}]},"item_5_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"中嶋, 遥美"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-04-20"}],"displaytype":"detail","filename":"KISYK9_Nakashima.pdf","filesize":[{"value":"725.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KISYK9_Nakashima.pdf","objectType":"fulltext","url":"https://nagasaki-u.repo.nii.ac.jp/record/26540/files/KISYK9_Nakashima.pdf"},"version_id":"4e544470-6f82-448c-b7f9-b5151310e8b8"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"differentiated thyroid carcinoma","subitem_subject_scheme":"Other"},{"subitem_subject":"lenvatinib","subitem_subject_scheme":"Other"},{"subitem_subject":"prognosis","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib.","subitem_title_language":"en"}]},"item_type_id":"5","owner":"6","path":["24"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-04-20"},"publish_date":"2021-04-20","publish_status":"0","recid":"26540","relation_version_is_last":true,"title":["Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib."],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-08-23T04:57:45.607322+00:00"}